303 related articles for article (PubMed ID: 31771820)
1. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
[TBL] [Abstract][Full Text] [Related]
2. Current and potential treatments for primary biliary cholangitis.
Shah RA; Kowdley KV
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
[TBL] [Abstract][Full Text] [Related]
3. Work in Progress: Drugs in Development.
Webb GJ; Hirschfield GM
Clin Liver Dis; 2018 Aug; 22(3):501-515. PubMed ID: 30259849
[TBL] [Abstract][Full Text] [Related]
4. Current Treatment Options for Primary Biliary Cholangitis.
Wong KA; Bahar R; Liu CH; Bowlus CL
Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies on Primary Biliary Cirrhosis.
Czul F; Levy C
Clin Liver Dis; 2016 Feb; 20(1):113-30. PubMed ID: 26593294
[TBL] [Abstract][Full Text] [Related]
6. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
7. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
8. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.
Hasegawa S; Yoneda M; Kurita Y; Nogami A; Honda Y; Hosono K; Nakajima A
Drugs; 2021 Jul; 81(10):1181-1192. PubMed ID: 34142342
[TBL] [Abstract][Full Text] [Related]
9. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Yokoda RT; Carey EJ
Am J Gastroenterol; 2019 Oct; 114(10):1593-1605. PubMed ID: 31169523
[TBL] [Abstract][Full Text] [Related]
10. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic advances for primary biliary cholangitis: the old and the new.
Wang L; Zhang FC; Zhang X
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):615-21. PubMed ID: 26862931
[TBL] [Abstract][Full Text] [Related]
13. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Gulamhusein AF; Hirschfield GM
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):93-110. PubMed ID: 31819247
[TBL] [Abstract][Full Text] [Related]
15. [New name and new treatments for primary biliary cholangitits].
Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Vetter C
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():56. PubMed ID: 26048128
[No Abstract] [Full Text] [Related]
18. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
19. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
Levy C
Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
[TBL] [Abstract][Full Text] [Related]
20. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Alawad AS; Levy C
Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
